RO6889450

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Healthy VolunteerSchizophrenia, Schizoaffective Disorder

Phase 1

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers

CompletedNCT02699372

Hoffmann-La RocheHealthy Volunteer

Start: 2016-03-21End: 2017-04-14Target: 164Updated: 2017-11-24

Phase 2

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

TerminatedNCT03669640

Hoffmann-La RocheSchizophrenia, Schizoaffective Disorder

Start: 2018-12-04End: 2023-03-12Updated: 2024-08-12

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

CompletedNCT04512066

Hoffmann-La RocheSchizophrenia, Schizoaffective Disorder

Start: 2020-09-08End: 2022-06-21Updated: 2023-10-10

Related Papers

Elucidating the molecular pharmacology of trace amine‐associated receptor 1 to advance antipsychotic drug discovery

Clinical and Translational Medicine2024-02-011 citations